<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828694</url>
  </required_header>
  <id_info>
    <org_study_id>BioCorRx-21-01a</org_study_id>
    <secondary_id>UG3DA047925</secondary_id>
    <nct_id>NCT04828694</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections</brief_title>
  <official_title>A Randomized, Open Label, Single Dose Pharmacokinetic and Safety Study of Implantable Long Acting 3-month Naltrexone Subcutaneous Pellets Compared to Naltrexone IM Injection (Vivitrol) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCorRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>BioCorRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, 6-month, open-label, multi-center study in parallel groups of randomized&#xD;
      healthy volunteers to evaluate the pharmacokinetics and safety of BICX104 implantable&#xD;
      subcutaneous naltrexone pellets and Vivitrol intramuscular depot naltrexone injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Cmax.</measure>
    <time_frame>140 Days</time_frame>
    <description>Maximum observed mean plasma concentration [Cmax] of naltrexone and 6-beta-naltrexol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Tmax.</measure>
    <time_frame>140 Days</time_frame>
    <description>Time to mean maximum observed drug concentration (Tmax) of naltrexone and 6-beta-naltrexol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Css.</measure>
    <time_frame>140 Days</time_frame>
    <description>Changes in the mean observed steady state plasma concentration [Css] of naltrexone and 6-beta-naltrexol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: AUC</measure>
    <time_frame>140 Days</time_frame>
    <description>Area Under the Plasma Concentration Versus Time Curve (AUC) of naltrexone and 6-beta-naltrexol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Tlast ≥ 1ng/ml naltrexone.</measure>
    <time_frame>140 Days</time_frame>
    <description>Time of Last Quantifiable Plasma Concentration (Tlast) of naltrexone greater than or equal to 1ng/ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Tlast.</measure>
    <time_frame>140 Days</time_frame>
    <description>Time of Last Quantifiable Plasma Concentration (Tlast) of naltrexone and 6-beta-naltrexol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Parameter: AEs</measure>
    <time_frame>168 Days</time_frame>
    <description>Incidence and severity of adverse events (AEs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>BICX104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BICX104 is an eroding implantable pellet that contains 1 g naltrexone and 11 mg magnesium stearate that will be inserted subcutaneously. It will be administered once for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vivitrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vivitrol intramuscular injection containing 380 mg of naltrexone. Three consecutive doses will be administered once every 28 days for 84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BICX104</intervention_name>
    <description>Erodable implantable pellet containing 1 g naltrexone and 11 mg magnesium stearate.</description>
    <arm_group_label>BICX104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vivitrol</intervention_name>
    <description>Intramuscular injection containing 380 mg of naltrexone.</description>
    <arm_group_label>Vivitrol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide informed consent.&#xD;
&#xD;
          2. Female or male subjects aged 18-50 years old&#xD;
&#xD;
          3. Without current non-remitted DSM-5 (The Diagnostic and Statistical Manual of Mental&#xD;
             Disorders, Fifth Edition) - Substance Use Disorders diagnoses; subjects with a&#xD;
             sustained remission diagnosis are not excluded.&#xD;
&#xD;
          4. In good health, as determined by the study physician, based on complete medical&#xD;
             history, physical examination, vital signs measurement, ECG, and laboratory tests&#xD;
             within normal ranges, to permit treatment.&#xD;
&#xD;
          5. Weight of 100-180 pounds, and a BMI of 18.5 to 30.0 kg/m2, inclusive.&#xD;
&#xD;
          6. Must agree to comply with all study requirements and be willing to complete entire&#xD;
             study.&#xD;
&#xD;
          7. Females of childbearing potential willing to practice an effective method of birth&#xD;
             control for the duration of participation in the study (double barrier method:&#xD;
             condoms, sponge, diaphragm, with spermicidal jellies, or cream).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is pregnant, is planning to become pregnant or breastfeed infants during the study.&#xD;
&#xD;
          2. Is currently treated with naltrexone or has had a naltrexone implant in the past 2&#xD;
             years or received Vivitrol treatment in the past year.&#xD;
&#xD;
          3. Clinically significant medical/psychological condition or abnormality at screening&#xD;
             (i.e., physical examination, electrocardiogram [ECG], hematology or blood chemistry&#xD;
             evaluation, or urinalysis findings), including any diagnosis of Hepatitis B, Hepatitis&#xD;
             C or HIV infection.&#xD;
&#xD;
          4. Presence of opiates, cocaine, methamphetamine or other significant drugs of abuse in&#xD;
             the urine (as determined by urine drug test).&#xD;
&#xD;
          5. Any active hepatitis or hepatic failure or dysfunction evidenced by the following:&#xD;
             aspartate transaminase (AST) or alanine transaminase (ALT) higher than 1.5 times the&#xD;
             upper limit of normal (1.5xULN), hyperbilirubinemia (bilirubin &gt;10% above ULN),&#xD;
             creatine phosphokinase (CPK) higher than 2.5xULN, prolonged prothrombin time&#xD;
             (international normalized ratio ≥1.7), ascites, or esophageal variceal disease.&#xD;
&#xD;
          6. Manifestation of suicidal ideation, psychotic symptoms (including significant violent&#xD;
             behavior), or psychiatric or neurological disorders that would compromise ability to&#xD;
             complete the study.&#xD;
&#xD;
          7. Participation in a methadone program currently or within past 3 years, or 3 or more&#xD;
             previous medically supervised detoxification treatments in past 3 years.&#xD;
&#xD;
          8. Failed naloxone challenge conducted by a clinician experienced in assessing withdrawal&#xD;
             symptoms (the challenge could be repeated up to 2 times, with at least 24 hours&#xD;
             between attempts).&#xD;
&#xD;
          9. Intolerance and/or hypersensitivity to naltrexone, naloxone, or&#xD;
             polylactide-co-polymers such as polylactide-co-glycolide (PLG).&#xD;
&#xD;
         10. Participation in a clinical trial within 30 days of screening.&#xD;
&#xD;
         11. Has a condition which requires or may require treatment with opioid based medication.&#xD;
&#xD;
         12. Is prone to skin rashes, irritation or has a chronic skin condition.&#xD;
&#xD;
         13. Alcohol Use Disorder diagnosis.&#xD;
&#xD;
         14. Has a predisposition to a poor response to an implant site reaction, as judged by the&#xD;
             study physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

